Brokerages Set Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Target Price at $14.00

Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) have been given a consensus recommendation of “Hold” by the nine ratings firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $14.00.

BCYC has been the topic of several research analyst reports. Needham & Company LLC dropped their price objective on Bicycle Therapeutics from $24.00 to $15.00 and set a “buy” rating on the stock in a research note on Wednesday, March 18th. Jefferies Financial Group reaffirmed a “buy” rating and set a $12.00 price objective on shares of Bicycle Therapeutics in a research note on Thursday, April 30th. Wall Street Zen downgraded Bicycle Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday, May 10th. Oppenheimer dropped their price objective on Bicycle Therapeutics from $44.00 to $36.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 18th. Finally, Citizens Jmp dropped their price objective on Bicycle Therapeutics from $12.00 to $8.00 and set a “market outperform” rating on the stock in a research note on Wednesday, March 18th.

Bicycle Therapeutics Stock Up 0.4%

BCYC stock opened at $4.69 on Monday. The business’s fifty day moving average is $4.75 and its 200-day moving average is $5.79. The company has a market cap of $326.93 million, a P/E ratio of -1.49 and a beta of 1.56. Bicycle Therapeutics has a twelve month low of $4.24 and a twelve month high of $9.36.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.25). The company had revenue of $0.89 million during the quarter, compared to analyst estimates of $7.50 million. Bicycle Therapeutics had a negative net margin of 344.95% and a negative return on equity of 35.74%. Research analysts anticipate that Bicycle Therapeutics will post -1.98 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Kevin Lee sold 5,967 shares of the firm’s stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $4.91, for a total transaction of $29,297.97. Following the sale, the chief executive officer owned 613,029 shares of the company’s stock, valued at approximately $3,009,972.39. This trade represents a 0.96% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 9,992 shares of company stock worth $49,363. Company insiders own 22.90% of the company’s stock.

Institutional Trading of Bicycle Therapeutics

Several hedge funds have recently added to or reduced their stakes in BCYC. Assetmark Inc. increased its holdings in Bicycle Therapeutics by 74.9% during the 3rd quarter. Assetmark Inc. now owns 3,625 shares of the company’s stock worth $28,000 after purchasing an additional 1,552 shares in the last quarter. Clearstead Advisors LLC increased its holdings in Bicycle Therapeutics by 234.2% during the 4th quarter. Clearstead Advisors LLC now owns 4,655 shares of the company’s stock worth $33,000 after purchasing an additional 3,262 shares in the last quarter. Pinnacle Wealth Management Advisory Group LLC bought a new position in Bicycle Therapeutics during the 4th quarter worth about $71,000. Ausdal Financial Partners Inc. bought a new position in Bicycle Therapeutics during the 2nd quarter worth about $70,000. Finally, Vontobel Holding Ltd. bought a new position in Bicycle Therapeutics during the 4th quarter worth about $71,000. Institutional investors and hedge funds own 86.15% of the company’s stock.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.